Trial Profile
A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Somatrogon (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors OPKO Health
- 06 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 14 Sep 2023 This trial has been completed in Bulgaria, according to European Clinical Trials Database record
- 12 Sep 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.